[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100500945":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":42,"responsibleParty":59,"collaborators":18,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":18,"enrollmentInfo":70,"targetDuration":18,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":79,"overallStatus":45,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Samara State Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"a group with the use of acetazolamide","EXPERIMENTAL","acetazolamide is prescribed at a dose of 250 mg 3 times a day",[13],"Drug: Acetazolamide",{"label":15,"type":16,"description":17,"interventionNames":18},"a group of standart therapy","NO_INTERVENTION","standart therapy includes main and additional medicine for treatment of chronic heart failure",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Acetazolamide","Acetazolamide is a diuretic with a mild diuretic effect. Inhibits the enzyme carbonic anhydrase in the proximal convoluted tubule of the nephron. Increases urinary excretion of sodium, potassium, bicarbonate ions, does not affect the excretion of chlorine ions; causes an increase in urine pH.",[9],[26],"diacarb",[28],{"name":29,"affiliation":30,"role":31},"Dmitriy Duplyakov","SamSMU","PRINCIPAL_INVESTIGATOR",[33,38],{"name":34,"role":35,"phone":36,"phoneExt":18,"email":37},"Dmitriy Duplyakov, MD","CONTACT","89277297273","Duplyakov@yahoo.com",{"name":39,"role":35,"phone":40,"phoneExt":18,"email":41},"Olesya Rubanenko, MD","89371887780","olesya.rubanenko@gmail.com",[43],{"facility":44,"status":45,"city":46,"state":18,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Samara state medical university","RECRUITING","Samara","443099","Russia","RU",{"type":51,"coordinates":52},"Point",[53,54],50.13553,53.20767,{"lat":54,"lon":53},[57],{"name":58,"role":35,"phone":40,"phoneExt":18,"email":41},"Olesya Rubanenko",{"type":60,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100500945","phase-4-acetazolamide-per-os-for-decompensation-of-heart-failure-100500945",false,"NCT05802849","Acetazolamide Per os for Decompensation of Heart Failure","ORION-A","Inclusion Criteria:\n\n* Men or women aged 18 years and older\n* Decompensated CHF NYHA II-IV, which required intravenous administration of diuretics\n* Any injection fraction of left ventricle\\*\n* Signed informed consent to participate in the study.\n\n  * in patients with LV LV ≥ 50%: the presence of structural changes of the heart# (left ventricular myocardial hypertrophy, enlargement of the left atrium) and\u002For diastolic dysfunction# and\u002For increased levels of BNP or NT-proBNP (BNP \\> 400 pg\u002Fml or NT-proBNP \\> 450 pg\u002Fml in persons younger 50 years old; \\> 900 pg\u002Fl in persons 51-75 years old; \\> 1800 pg\u002Fml older than 75 years) #.\n\n    * criteria according to clinical guidelines 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829\u002F1560-4071-2020-4083\n\nExclusion Criteria:\n\n* Acetazolamide therapy for a month before hospitalization.\n* The expected intravenous use of inotropes, vasopressors or sodium nitroprusside at any time of the study.\n* Exposure to nephrotoxic agents (e.g. contrast dye) is expected within the next 3 days.\n* Hypersensitivity to acetazolamide, other sulfonamides and \u002F or components of the drug.\n* Systolic blood pressure \\\u003C90 mmHg.\n* Pregnancy and lactation.\n* Hypokalemia (potassium \\\u003C 3.5 mmol\u002Fl).\n* Hyponatremia (sodium \\\u003C135 mmol\u002Fl).\n* Severe chronic renal insufficiency (creatinine clearance less than 10 ml\u002Fmin) or the use of renal replacement therapy or ultrafiltration at any time prior to inclusion in the study.\n* Metabolic acidosis (bicarbonate less than 12 mmol\u002FL).\n* Severe anemia (Hb \\\u003C70 g\u002FL).\n* Acute renal failure.\n* Addison's disease.\n* Decompensated diabetes mellitus.\n* Emergency conditions (myocardial infarction, pulmonary embolism, acute myocarditis, pericarditis, aortic aneurysm).\n* Cirrhosis of the liver with encephalopathy and liver failure.\n* Congenital heart defects.\n* Malignant neoplasm in the phase of active treatment or terminal form of cancer.\n* Hypocorticism.","ALL","18 Years",{"count":71,"type":72},400,"ESTIMATED","INTERVENTIONAL",[75],"PHASE4","The main causes of chronic heart failure (CHF) are arterial hypertension and coronary artery disease, less often cardiomyopathy, pericarditis, metastatic myocardial lesions. It should be noted that up to 50% of patients have a preserved left ventricular ejection fraction (LVEF), while its prevalence is progressively increasing annually.\n\nAcute decompensation of CHF is understood as a rapid increase in the severity of clinical manifestations (shortness of breath, severe arterial hypoxemia, the occurrence of arterial hypotension), which caused urgent medical treatment and emergency hospitalization in a patient already suffering from CHF. Decompensation of CHF requires intensification of treatment in order to stabilize the patient's condition. Strengthening diuretic therapy in addition to standard therapy helps to reduce edematous syndrome.",[78],"Chronic Heart Failure",[80,81],"acetazolamide","edema syndrome","2024-11-02",{"date":84,"type":85},"2024-11-05","ACTUAL",{"date":87,"type":85},"2023-05-01",{"date":89,"type":72},"2025-12-01",{"name":5,"class":6},1]